BofA update shows where active managers are putting money
In a recent transaction, Christian Angermayer, director and significant shareholder of ATAI Life Sciences N.V. (NASDAQ:ATAI), has acquired 1.8 million common shares at $1.40 each. The purchase, conducted through Apeiron Investment Group Ltd., a company in which Angermayer holds a major interest, amounted to a total of $2.52 million. Following this transaction, Angermayer’s indirect ownership through Apeiron Investment Group Ltd. stands at over 42.3 million shares. The purchase price represents a significant discount to the current trading price of $1.57, with the stock showing strong momentum, up nearly 23% over the past six months. InvestingPro data reveals the company maintains a healthy balance sheet with more cash than debt and a current ratio of 3.21.
This acquisition underscores Angermayer’s continued confidence in ATAI Life Sciences, a company engaged in pharmaceutical preparations, as it seeks to advance its position in the life sciences sector. While the company is currently unprofitable with an EBITDA of -$99.3M, its strong liquidity position suggests runway for continued operations. Unlock more insights about ATAI’s insider trading patterns and 8 additional key InvestingPro Tips to make informed investment decisions.
In other recent news, ATAI Life Sciences has completed patient enrollment for its global Phase 2b clinical trial of BPL-003, targeting treatment-resistant depression. This trial, which involves 196 patients, is the largest controlled study of mebufotenin to date and aims to evaluate the efficacy and safety of the drug. Additionally, ATAI reported promising preliminary results from a Phase 2a study of BPL-003 for alcohol use disorder, demonstrating a significant reduction in alcohol consumption when combined with cognitive behavioral therapy. The company also announced a $5 million investment in Bitcoin as part of its treasury reserve strategy, reflecting a growing trend among corporations to include digital assets in their portfolios. In corporate governance news, Michael Auerbach has resigned from ATAI’s supervisory board, reducing its membership from seven to six. Furthermore, ATAI has made significant changes to its executive team, with Dr. Srinivas Rao assuming the role of sole CEO and other key leadership appointments. These developments come as ATAI advances its clinical trials for novel therapeutics, including VLS-01 and EMP-01, aimed at treating mental health conditions. The company continues to focus on evidence-based therapies to address unmet medical needs in mental health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.